ALD518 is a Phase II Humanized Monoclonal Antibody Targeting IL-6 PRINCETON, N.J. & BOTHELL, Wash., Nov 10 –(HSMN NewsFeed)– Bristol-Myers Squibb Company (NYSE:BMY ) and Alder Biopharmaceuticals, Inc., today announced a global agreement for the develo…
Biopharmaceuticals
Bristol-Myers Squibb, Alder Biopharmaceuticals, ALD518, rheumatoid arthritis

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “Bristol-Myers Squibb and Alder Biopharmaceuticals Enter Global Agreement on Rheumatoid Arthritis Biologic”
Leave a Comment